Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. (Q30373740)

21 June 2017

Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. (English)

1 reference

21 June 2017

0 references

4

L van Alphen

1 reference

21 June 2017

J J C de Vries

1

1 reference

21 June 2017

L Bungener

2

1 reference

21 June 2017

W Ter Veer

3

1 reference

21 June 2017

P van der Ley

5

1 reference

21 June 2017

J Wilschut

6

1 reference

21 June 2017

A Huckriede

7

1 reference

21 June 2017

language of work or name

English

0 references

publication date

4 December 2008

1 reference

21 June 2017

1 reference

21 June 2017

27

1 reference

21 June 2017

6

1 reference

21 June 2017

947-955

1 reference

Vaccines for pandemic influenza

21 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Scientific barriers to developing vaccines against avian influenza viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

The virosome concept for influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Clinical experience with inactivated, virosomal influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Immunogenicity of new virosome influenza vaccine in elderly people

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

The perfect mix: recent progress in adjuvant research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Reversal of age-related deficient influenza virus-specific CTL responses and IFN-gamma production by monophosphoryl lipid A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Innate immune sensing and its roots: the story of endotoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Expression of the lipopolysaccharide-modifying enzymes PagP and PagL modulates the endotoxic activity of Bordetella pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

A new and improved microassay to determine 2-keto-3-deoxyoctonate in lipopolysaccharide of gram-negative bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Use of a dialyzable short-chain phospholipid for efficient solubilization and reconstitution of influenza virus envelopes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

A simplification of the protein assay method of Lowry et al. which is more generally applicable

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

A rapid and sensitive sub-micro phosphorus determination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Increased resolution of lipopolysaccharides and lipooligosaccharides utilizing tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Evaluation of viral membrane fusion assays. Comparison of the octadecylrhodamine dequenching assay with the pyrene excimer assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Virosome-mediated delivery of protein antigens to dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Quantification of antigen specific CD8+ T cells using an ELISPOT assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Toll-dependent selection of microbial antigens for presentation by dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

A critical contribution of both CD28 and ICOS in the adjuvant activity of Neisseria meningitidis H44/76 LPS and lpxL1 LPS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

Stimulatory effects of B7-related protein-1 on cellular and humoral immune responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.11.046

10.1016/J.VACCINE.2008.11.046

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference